ZTSNYSEThe short version
Zoetis Inc.
Zoetis is the world's largest animal-health company — patent-protected medicines, vaccines and diagnostics for pets and livestock — whose shares have fallen about 69% from their 2021 peak as US pet-care demand cooled and growth slowed.
From a late-2021 peak near $247 the shares only fell — a slide to about $76 by mid-2026, most of it in the final year as management cut guidance twice.
$76
Share price
$32B
Market cap
$9.5B
Revenue FY2025
78%
Return on equity
SwipeScroll▾
The statements
A high-return compounder whose growth stepped down in 2025
FY2020 → FY2025as reported · $
Revenue$9.5B+2%
Net income$2.7B+8%
EPS$6.02+10%
Free cash flow$2.3B−1%
Open the full statements →As-reported income and cash-flow statements, FY2020–FY2025.
- Revenue. Sales grew from $6.7B in 2020 to $9.47B in 2025, but reported growth slowed to about 2% from 8% in 2024, and Q1 FY2026 organic revenue was flat.
- Profit. Net income reached $2.67B on a ~28% net margin, with basic EPS of $6.03 and a return on equity near 78% — earnings at record levels.
- Cash. Free cash flow was $2.28B, yet the company returned $4.12B to shareholders — about 1.8 times cash generated — funding the gap with new debt.
Margin of safety
The price embeds almost no growth against a mid-single-digit runway
~11x
Forward P/Eon ~$6.86 consensus EPS
7.1%
Free-cash-flow yield
12.6x
Trailing P/Evs a low-30s history
−69%
From the 2021 peak
Valuation at a share price near $76 (July 18, 2026).
- Priced for low growth. At about $76, Zoetis trades near 11 times forward earnings and a 7% free-cash-flow yield — roughly a third of its historical multiple — which embeds only 2–3% long-run growth against a mid-single-digit runway and consensus earnings growth near 7%.
- The discount is partly earned. Growth has genuinely slowed, FY2026 organic revenue is guided to 2–5%, and the pre-2022 low-30s multiple may prove a ceiling rather than a way-point if the US companion business does not re-accelerate.
- Asymmetric. A re-rating merely to the mid-teens — a base near $96 — is about 27% up, while a bear case of ~$60 on a second stumble is about 21% down.
Growth runway
The weakness spread into the franchises meant to be the offset
Q1 FY2026 organic growth by area
Newer companion franchises turned negative; diagnostics and livestock kept growing.
- The 'breadth carries growth' answer held in FY2025 — livestock +8% and diagnostics +13% lifted group organic growth to +6% while US companion growth flattened — but in Q1 FY2026 the weakness spread into the newer companion franchises meant to be the offset (key dermatology −11%, Librela −13%, OA-pain mAbs −8%), pulling companion animal down 4% and testing whether the diversified portfolio can still carry the group.
- Bending, not broken. Diagnostics (+10%) and livestock (+12%) kept growing in Q1 FY2026 and do not share the US pet-visit cycle that is pulling companion animal down.
- The stake. If diagnostics, livestock and international also roll over, the 2–5% organic guide becomes the ceiling rather than the floor — against a pipeline of 12 candidate blockbusters yet to prove at scale.
The de-rating
Earnings near records, the multiple cut to a third of its history
Trailing P/E, year-end
Year-end close ÷ that year's EPS; the 2026 point is mid-July on 2025 EPS.
- A multiple story. EPS sits near a record $6.03, yet the stock trades at about 12.6 times trailing earnings — well below the low-to-mid-30s it carried for most of its public life.
- Two legs down. The multiple began falling in 2022 as earnings grew into a still-high price; the sharper leg — from ~21x to 12.6x in 2026 — followed the Q1 guidance cut.
- Not capitulation. The sell-side softened but held: a consensus target near $115, a ratings split of roughly 11 buy to 9 hold, and no sells.
What Zoetis is
A business that has tilted steadily toward pets
FY2025 revenue by species group
Companion animal$6,587M70%
Livestock$2,764M29%
Other$116M1%
Companion animal was about 70% of 2025 revenue.
- Pets are the engine. Companion-animal products were roughly 70% of 2025 revenue ($6.59B); livestock is most of the balance ($2.76B). That tilt is the growth story and, lately, the problem.
- Concentrated. Simparica is about 16% of revenue and Apoquel about 12%; the top five brands reach ~42% and the top ten about 57%.
- No owner-operator. Eight core species, seven categories; carved out of Pfizer, taken public in 2013, with no founder or controlling shareholder.
Franchise moat
A decade of widening margins — the moat shows in the numbers
Gross margin, FY2016–FY2025
Animal health never grew a scaled generic industry, so patent cliffs erode slowly.
- Pricing power. Gross margin climbed from 65.9% in 2016 to 71.8% in 2025; in mid-2024 Zoetis was adding roughly 6 points of price to 3 of volume. Raising price while holding share is a moat at work.
- Franchise-bounded. The moat is really a handful of patented franchises — the top five brands are ~42% of revenue — each with its own patent clock.
- Erosion is real. When Draxxin's patent lapsed, its US sales fell 66%; today's pressure, though, is branded rivals, not generics, in the key companion categories.
Demand diagnosis
US clinic visits have fallen four years running
US veterinary visits, annual change
Independent practice-transaction data (~6,500 US practices), not a company disclosure.
- The offset broke. For a decade Zoetis grew through falling traffic by expanding categories and spend per visit; in Q1 FY2026 US companion revenue fell 11% as visits dropped across every major therapeutic area.
- Structural, with a transient overlay. Market-wide visit erosion looks secular, though storms, destocking and a ~$100M calendar shift flattered the quarter.
- The engine still runs abroad. Where categories are still expanding, international companion grew 7% and international Simparica 14% in the same quarter.
Cash conversion
The reported margin is spendable cash, not accounting profit
$2.28B
Free cash flow FY2025
24%
Free-cash-flow margin
1.09x
Operating cash flow / net income
86%
10-yr free cash flow / net income
Cash conversion held through the demand stall.
- Cash-backed earnings. Operating cash flow topped net income in eight of ten years — about $20.1B against $17.9B over the decade — with little stock comp and light intangible amortization.
- Downside protection. The business threw off $2.28B of free cash flow in a year its US companion engine stalled, the core of the case's floor.
- The caveat. A $2.46B inventory book — about 337 days, built for demand that has since softened — carries a live write-down risk and makes cash lumpy.
Capital allocation
In 2025 shareholder returns outran the cash that funded them
Shareholder returns vs free cash flow
2025 returns reached 1.8x free cash flow, the gap bridged with new debt.
- Debt-funded returns. Zoetis returned $4.12B in 2025 — 1.8 times free cash flow — raising a $2.0B convertible and $1.85B of notes; net debt rose to about $6.6B.
- Poorly timed, so far. The buyback shrank the share count ~9% since 2022, but at $136–178 a share against the ~$76 the stock later reached.
- Time decides. If the business reaccelerates the purchases look astute; if the de-rating is structural, they read as debt raised to prop a falling stock.
Ownership and balance sheet
Clean governance and a sound balance sheet, one ingredient missing
<1%
Insider ownershipno founder
1.6x
Net debt / EBITDAcovenant 3.5x
~16x
Interest coverage
$0.9M
Director buys, May 2026near the lows
The bankruptcy and governance screens both clear.
- Solvency clears. Net debt runs about 1.6x EBITDA against a 3.5x covenant, interest is covered roughly 16 times, and nothing matures in 2026.
- Governance is clean. The board is 11 of 12 independent with an independent chair, one share one vote and annual elections — none of the usual red flags.
- The missing ingredient. Directors and officers hold under 1% and there is no founder, though three directors bought about $886k in the open market near the mid-2026 lows.
Valuation vs peers
The cheapest of the profitable animal-health names
Quality peers, FY2025
| Company | Mkt cap ($B) | Trailing P/E | Net margin |
|---|---|---|---|
| Zoetis | 31.9 | 12.6x | 28% |
| IDEXX | 44.6 | 43x | 25% |
| Elanco | 12.8 | n/m | −5% |
FY2025 filings and market prices; Elanco's P/E is not meaningful on a net loss.
- Least expensive. Among companies that convert animal-health revenue to profit at scale, Zoetis is now the cheapest — 12.6x trailing versus IDEXX's ~43x.
- Partly earned. IDEXX grows faster on a razor-and-blade diagnostics model, so a gap is warranted — but this wide a gap on a higher net margin is hard to defend.
- The instructive contrast. Elanco's lack of a meaningful multiple, on a 2025 loss, shows a 28% margin is Zoetis's achievement, not the industry default.
Scenarios
A real margin of safety, but conditional on demand troughing
Scenario value band vs ~$76
Bear — second cut, 10x
$60
Base — 14x 2026 EPS
$96
Sell-side mean target
$115
Bull — 18x 2027 EPS
$133
Multiples applied to consensus adjusted EPS; sell-side mean target ~$115.
- Asymmetric. A re-rating merely to the mid-teens (base ~$96) is about 27% above the price, while a second stumble (bear ~$60) is about 21% below it.
- Conditional. The gap is compensation for a demand recovery that has not yet appeared in the numbers — a margin of safety, not a discount independent of the demand question.
- The swing factor. The band is most sensitive to whether US companion demand troughs in the second or third quarter of 2026.
What to watch
Priced for little growth: cheap if US demand troughs on schedule, a value trap if the slowdown proves structural.
- 01US companion organic growth — the Q2 FY2026 print in early August is the first noise-free read: positive supports the base case, another decline points to the bear.
- 02Full-year 2026 guidance — a second cut to the 2–5% organic range points toward ~$60; a hold or raise supports the base near $96.
- 03Librela's US trend and dermatology share — sustained sequential recovery would lift the case for the new-category pipeline.
- 04Buyback pace and net debt/EBITDA — repurchases below $80 with leverage under the 3.5x covenant would strengthen the capital-allocation read.
This distills a guided study built chapter by chapter — statements, moat, demand, cash, capital, growth, valuation, and scenarios.
Compiled from the full report · 2026-07-20 · For information, not investment advice.